Ignite Creation Date:
2024-05-06 @ 10:09 AM
Last Modification Date:
2024-10-26 @ 12:25 PM
Study NCT ID:
NCT03178851
Status:
COMPLETED
Last Update Posted:
2021-11-19
First Post:
2017-06-01
Brief Title:
Cobimetinib Targeted Therapy Plus Atezolizumab Immunotherapy in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Organization Data
Organization:
Hoffmann-La Roche
Class:
INDUSTRY
Study ID:
CO39721
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hoffmann-La Roche
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None